Empagliflozin
| Grade | Pharmaceutical |
| Pharmacopoeia | In house |
| CAS No. | 864070-44-0 |
| Product Name | Empagliflozin |
| Chemical Name | (2S,3R,4R,5S,6R)-2-[4-Chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol |
| Function | Active Pharmaceutical Ingredients (APIs) |
| Industrial Application | Pharmaceutical |
| Category | Antidiabetic type 2 |
General Description
Empagliflozin is a medication used in the management and treatment of type 2 diabetes mellitus. It works in the kidneys to prevent the absorption of glucose in order to lower blood sugar levels. It is not useful for insulin-dependent or type 1 diabetes. It is also used in adults with heart failure to reduce the risk of hospitalization and death due to heart disease. It belongs to a class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors.
Physical Characteristics
| Molecular formula | C₂₃H₂₇ClO₇ |
| Molecular weight | 450.91 |
| Appearance | White or off white, crystalline powder |
| Solubility | Soluble in DMSO, sparingly soluble in methanol, practically insoluble in water |
| Water | Maximum 0.5% |
| Specific optical rotation | 15 to 20 |
| Heavy metals | Maximum 20 ppm |
| Residue on ignition | Maximum 0.1% |
| Purity | Minimum 99.7% |
| Assay | 98.0% to 102.0% (dried substance) |
| Storage | Preserve in a well-closed container. Store at controlled room temperature |
| Stability | Stable at least 2 years at room temperature |